Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7800 (1.6%) ($10.6200 - $10.7800) on Fri. Nov. 17, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.33% (three month average) | RSI | 50 | Latest Price | $10.7800(1.6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.6% a day on average for past five trading days. | Weekly Trend | FOLD declines -2.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IVW(89%) SPY(82%) SMH(81%) QQQ(75%) IBB(74%) | Factors Impacting FOLD price | FOLD will decline at least -1.665% in a week (0% probabilities). TBT(-40%) VXX(-34%) UUP(-19%) URA(-10%) VIXM(1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.665% (StdDev 3.33%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $10.87 | 5 Day Moving Average | $10.61(1.6%) | 10 Day Moving Average | $10.77(0.09%) | 20 Day Moving Average | $10.87(-0.83%) | To recent high | -19.2% | To recent low | 8.2% | Market Cap | $2.784b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |